Orasis Pharmaceuticals: Funding, Investors & Team (Sep 2026)
Orasis Pharmaceuticals develops a corrective eye drop to treat presbyopia. The company's product, CSF-1, is an eye drop that improves the quality of life for people with presbyopia by alleviating the burden of reading glasses. By repurposing existing and well-studied molecules, CSF-1 is designed to be effective and also safe, comfortable, and easy-to-use.
Orasis Pharmaceuticals has raised $30.0M across 1 funding round on record, the most recent an undisclosed round of $30.0M announced in Sep 2020.
That round is above the $4.7M median round size for Health Care companies tracked on FundedIQ over the last two years.
Orasis Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Sep 2020.
Orasis Pharmaceuticals Funding Rounds
Orasis Pharmaceuticals Founders and Leadership Team
Contact details for the Orasis Pharmaceuticals team: 1 of 1 has an email address on file.
Start 14-day free trial →Orasis Pharmaceuticals Funding Compared to Other Health Care Startups
Orasis Pharmaceuticals' latest round of $30.0M is above the median round in Health Care. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Orasis Pharmaceuticals in Health Care and Herzliya
Companies Similar to Orasis Pharmaceuticals
QuantHealth is an organization that produces software using artificial intelligence technology for drug…
Inspira Technologies is a cutting-edge medical technology company that specializes in the acute respiratory…
Alpha Tau Medical is an Israeli medical device company that focuses on research, development and…
Adenocyte is a privately held medical technology business that focuses on early diagnosis of adenocarcinoma…
Vortex Imaging develops medical imaging devices.
Urologic Health developing innovative solutions to improve bladder function diagnosis, monitoring, and…
VISIONIX develops, manufactures and distributes innovative equipment and provides a complete solution for…
Fize Medical is a health care company based in Israel.
Synchrony Medical is a clinical stage medical device company developing LibAirty, a next generation,…
TopGum has developed a highly scalable patent-pending delivery system with the capacity to deliver a wide…
Nanox offers the Nanox System as a preventative healthcare Medical Screening As A Service (MSaaS). Nanox…
Microbot Medical is a company that creates innovative medical devices using micro-robotic technology. They…
Orasis Pharmaceuticals Funding FAQs
What does Orasis Pharmaceuticals do?
Orasis Pharmaceuticals develops a corrective eye drop to treat presbyopia. The company's product, CSF-1, is an eye drop that improves the quality of life for people with presbyopia by alleviating the burden of reading glasses. By repurposing existing and well-studied molecules, CSF-1 is designed to be effective and also safe, comfortable, and easy-to-use.
How much funding has Orasis Pharmaceuticals raised?
Orasis Pharmaceuticals has raised $30.0M across 1 round on record. The most recent is an undisclosed round of $30.0M announced in Sep 2020.
When did Orasis Pharmaceuticals last raise funding?
Orasis Pharmaceuticals' most recent funding round on record is an undisclosed round of $30.0M, announced in Sep 2020.
Who is the CEO of Orasis Pharmaceuticals?
Elad Kedar is listed as CEO at Orasis Pharmaceuticals.
Where is Orasis Pharmaceuticals headquartered?
Orasis Pharmaceuticals is based in Herzliya, Tel Aviv, Israel.
How many employees does Orasis Pharmaceuticals have?
Orasis Pharmaceuticals is in the 1-10 employee band.
How does Orasis Pharmaceuticals' funding compare to other Health Care startups?
Orasis Pharmaceuticals' latest round of $30.0M is above the $4.7M median round size for Health Care companies on FundedIQ across 3,653 tracked companies over the last two years.
About FundedIQ's Orasis Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Orasis Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.